Anti-MEK and Anti-EGFR mAbs in RAS-Mutant Metastatic Colorectal Cancer: Case Series and Rationale

Overview of attention for article published in Advances in Therapy, April 2019

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (51st percentile)
Above-average Attention Score compared to outputs of the same age and source (55th percentile)

Mentioned by

twitter: 7 X users

Readers on

mendeley: 30 Mendeley

Summary X

So far, Altmetric has seen 7 X posts from 7 X users, with an upper bound of 4,721 followers.

RT @AdvancesTherapy: Just published "Anti-MEK and Anti-EGFR mAbs in RAS-Mutant Metastatic #ColorectalCancer: Case Series and Rationale". Re…

07 Jun 2019

Reply Repost Favourite

RT @AdvancesTherapy: Just published "Anti-MEK and Anti-EGFR mAbs in RAS-Mutant Metastatic #ColorectalCancer: Case Series and Rationale". Re…

15 Apr 2019

Reply Repost Favourite

Anti-MEK and Anti-EGFR mAbs in RAS-Mutant Metastatic Colorectal Cancer: Case Series and Rationale. https://t.co/8rRU9ywbIB

14 Apr 2019

Reply Repost Favourite

#MTB cancerassassin1 shilpaonc Anti-MEK and Anti-EGFR mAbs in RAS-Mutant Metastatic Colorectal Cancer: Case Series and Rationale. https://t.co/lIKSK7cz2A

14 Apr 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 3 additional X posts.